{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:48:30Z","timestamp":1794271710952,"version":"4.9.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100031527","name":"Sichuan University of Arts and Science","doi-asserted-by":"publisher","award":["XCH2024ZB-13"],"award-info":[{"award-number":["XCH2024ZB-13"]}],"id":[{"id":"10.13039\/100031527","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bioorg.2026.109537","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:21:25Z","timestamp":1769098885000},"page":"109537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Inhibition of the NLRP3 pathway as a strategy for SLE therapy"],"prefix":"10.1016","volume":"171","author":[{"given":"Jing","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109537_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic Lupus Erythematosus","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2026.109537_bb0010","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bioorg.2026.109537_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: Diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bioorg.2026.109537_bb0020","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bioorg.2026.109537_bb0025","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3899\/jrheum.190733","article-title":"Association Between Cigarette Smoking and Systemic Lupus Erythematosus: An Updated Multivariate Bayesian Metaanalysis","volume":"47","author":"Chua","year":"2020","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/rheumatology\/keaa444","article-title":"Systematic review and meta-analysis of epidemiological studies on the association of occupational exposure to free crystalline silica and systemic lupus erythematosus","volume":"60","author":"Morotti","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0035","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1177\/09612033221129774","article-title":"Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies","volume":"31","author":"Cai","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.bioorg.2026.109537_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2023-224762","article-title":"Response to: Correspondence on 'EULAR recommendations for the management of systemic lupus erythematosus: 2023 update' by Fanouriakis et al","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bioorg.2026.109537_bb0045","article-title":"Lupus Nephritis in Children: Novel Perspectives","volume":"59","author":"Pennesi","year":"2023","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0050","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic Lupus Erythematosus: A Review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2026.109537_bb0055","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0060","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109537_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114147","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective","volume":"180","author":"Bindu","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.gastrohep.2021.06.003","article-title":"NSAIDs, gastrointestinal toxicity and inflammatory bowel disease","volume":"45","author":"Hijos-Mallada","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0075","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08820139.2023.2289066","article-title":"A State-of-the-Art Review on the Recent Advances of Mesenchymal Stem Cell Therapeutic Application in Systematic Lupus Erythematosus","volume":"53","author":"Karimi","year":"2024","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.bioorg.2026.109537_bb0080","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","article-title":"NLRP3 inflammasome in cancer and metabolic diseases","volume":"22","author":"Sharma","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109537_bb0090","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/art.38174","article-title":"P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3\/ASC\/caspase 1 pathway","volume":"65","author":"Zhao","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bioorg.2026.109537_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1346656","article-title":"Exploring the ROS reduction strategies in chronic lupus management","volume":"15","author":"Kannan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122686","article-title":"Unmasking the NLRP3 inflammasome in dendritic cells as a potential therapeutic target for autoimmunity, cancer, and infectious conditions","volume":"348","author":"Alipour","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0105","doi-asserted-by":"crossref","DOI":"10.1161\/hyp.81.suppl_1.P146","article-title":"Abstract P146: Sex-Dependent Regulation of the Endothelin System in Multi-End Organ Inflammation in Lupus-Associated Cardiovascular Disease","volume":"81","author":"McCrorey","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.bioorg.2026.109537_bb0110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","article-title":"Targeting the NLRP3 inflammasome for inflammatory disease therapy","volume":"46","author":"Cabral","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.591393","article-title":"Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis","volume":"11","author":"Ding","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0120","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1002\/ptr.7118","article-title":"Medicinal plants and bioactive natural products as inhibitors of NLRP3 inflammasome","volume":"35","author":"Bagherniya","year":"2021","journal-title":"Phytother. Res. PTR"},{"key":"10.1016\/j.bioorg.2026.109537_bb0125","article-title":"The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors","volume":"13","author":"Zhan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0135","doi-asserted-by":"crossref","first-page":"R280","DOI":"10.1186\/cc10564","article-title":"Clinical relevance of single nucleotide polymorphisms within the entire NLRP3 gene in patients with major blunt trauma","volume":"15","author":"Zhang","year":"2011","journal-title":"Crit. Care (London, England)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0140","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109537_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102717","article-title":"The leucine-rich repeat (LRR) domain of NLRP3 is required for NLRP3 inflammasome activation in macrophages","volume":"298","author":"Duan","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109537_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212476","article-title":"The Role of NLRP3 Inflammasome in Lupus Nephritis","volume":"22","author":"Oliveira","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0155","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1242\/jcs.207365","article-title":"Inflammasome activation and assembly at a glance","volume":"130","author":"Malik","year":"2017","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0160","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J. Immunol. (Baltimore Md.: 1950)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0165","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109537_bb0170","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00011-020-01354-w","article-title":"Inflammasome activation in podocytes: a new mechanism of glomerular diseases","volume":"69","author":"Xiong","year":"2020","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bioorg.2026.109537_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2X7 Receptor in Infection and Inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2026.109537_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.109537_bb0185","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4049\/jimmunol.1100613","article-title":"Cutting Edge: Reactive Oxygen Species Inhibitors Block Priming, but Not Activation, of the NLRP3 Inflammasome","volume":"187","author":"Bauernfeind","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0190","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109537_bb0195","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4049\/jimmunol.212.supp.0180.4791","article-title":"NEK7 phosphorylation amplifies NLRP3 inflammasome activation downstream of gasdermin D and potassium efflux","volume":"212","author":"Xu","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0200","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-01919-w","article-title":"Identification of a covalent NEK7 inhibitor to alleviate NLRP3 inflammasome-driven metainflammation","volume":"22","author":"Jin","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2026.109537_bb0205","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1073\/pnas.2316551121","article-title":"Inhibition of NLRP3 inflammasome activation by A20 through modulation of NEK7","volume":"121","author":"Yu","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0210","first-page":"845","article-title":"Mechanistic study of P2X7\/NLRP3 pathway in the pathogenesis of lupus nephritis in mice[in Chinese]","volume":"32","author":"Zhao","year":"2016","journal-title":"Chin. J. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0215","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.4049\/jimmunol.176.7.3877","article-title":"The P2X7 receptor: a key player in IL-1 processing and release","volume":"176","author":"Ferrari","year":"2006","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0220","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1152\/physrev.00015.2002","article-title":"Molecular physiology of P2X receptors","volume":"82","author":"North","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bioorg.2026.109537_bb0225","doi-asserted-by":"crossref","first-page":"C790","DOI":"10.1152\/ajpcell.00072.2012","article-title":"P2X7 receptor activation induces inflammatory responses in salivary gland epithelium","volume":"303","author":"Woods","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0230","doi-asserted-by":"crossref","DOI":"10.1186\/s12950-018-0192-9","article-title":"Expression and clinical significance of the NEK7-NLRP3 inflammasome signaling pathway in patients with systemic lupus erythematosus","volume":"15","author":"Ma","year":"2018","journal-title":"J. Inflamm."},{"key":"10.1016\/j.bioorg.2026.109537_bb0235","doi-asserted-by":"crossref","first-page":"ra38","DOI":"10.1126\/scisignal.2002767","article-title":"Interferon-\u03b2 therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome","volume":"5","author":"Inoue","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bioorg.2026.109537_bb0240","article-title":"Truncating NFKB1 variants cause combined NLRP3 inflammasome activation and type I interferon signaling and predispose to necrotizing fasciitis","volume":"5","author":"Nurmi","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bioorg.2026.109537_bb0245","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.immuni.2024.09.004","article-title":"Type I IFN drives unconventional IL-1\u03b2 secretion in lupus monocytes","volume":"57","author":"Caielli","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2026.109537_bb0250","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5582\/bst.2020.01029","article-title":"NEK7: a potential therapy target for NLRP3-related diseases","volume":"14","author":"Liu","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.bioorg.2026.109537_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102515","article-title":"Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors","volume":"113","author":"Zhao","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bioorg.2026.109537_bb0260","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0265","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.it.2022.10.007","article-title":"Humans pIKK-up NLRP3 to skip NEK7","volume":"43","author":"Malireddi","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0270","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-025-00653-y","article-title":"Lupus nephritis","volume":"11","author":"Parodis","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bioorg.2026.109537_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116679","article-title":"NLRP3 inflammasome and its role in autoimmune diseases: A promising therapeutic target","volume":"175","author":"Ren","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109537_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109221","article-title":"Renal NLRP3 Inflammasome activation is associated with disease activity in lupus nephritis","volume":"247","author":"Chen","year":"2023","journal-title":"Clin. Immunol. (Orlando, Fla.)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0285","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.40155","article-title":"Podocyte Activation of NLRP3 Inflammasomes Contributes to the Development of Proteinuria in Lupus Nephritis","volume":"69","author":"Fu","year":"2017","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.014","article-title":"Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation","volume":"103","author":"Guo","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bioorg.2026.109537_bb0295","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/art.38993","article-title":"Lupus nephritis: glycogen synthase kinase 3\u03b2 promotion of renal damage through activation of the NLRP3 inflammasome in lupus-prone mice","volume":"67","author":"Zhao","year":"2015","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0300","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1136\/annrheumdis-2014-205496","article-title":"NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-\u03b2 receptor signalling","volume":"74","author":"Lech","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bioorg.2026.109537_bb0305","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0310","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/385297","article-title":"Effect of Proinflammatory Cytokines (IL-6, TNF-\u03b1, and IL-1\u03b2) on Clinical Manifestations in Indian SLE Patients","volume":"2014","author":"Umare","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bioorg.2026.109537_bb0315","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.4049\/jimmunol.167.12.7060","article-title":"Role of IL-18 in Acute Lung Inflammation","volume":"167","author":"Jordan","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0320","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/08820139.2023.2215280","article-title":"Study of NLRP3 Single Nucleotide Polymorphisms in Juvenile Systemic Lupus Erythematosus (JSLE)","volume":"52","author":"Yazdanpanah","year":"2023","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.bioorg.2026.109537_bb0325","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.2293","article-title":"Activation of NLRP3 Inflammasome in the Skin of Patients with Systemic and Cutaneous Lupus Erythematosus","volume":"102","author":"M\u00e4h\u00f6nen","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0330","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/annrheumdis-2021-221985","article-title":"Tfh cells with NLRP3 inflammasome activation are essential for high-affinity antibody generation, germinal centre formation and autoimmunity","volume":"81","author":"Zhao","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109537_bb0335","article-title":"The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice","volume":"13","author":"Yuji","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.109537_bb0340","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","article-title":"Signaling pathways of chronic kidney diseases, implications for therapeutics","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109537_bb0345","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41401-023-01094-7","article-title":"Bergapten inhibits NLRP3 inflammasome activation and pyroptosis via promoting mitophagy","volume":"44","author":"Luo","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2026.109537_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/cells9091948","article-title":"Loganin Attenuates High Glucose-Induced Schwann Cells Pyroptosis by Inhibiting ROS Generation and NLRP3 Inflammasome Activation","volume":"9","author":"Cheng","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.109537_bb0355","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.7150\/thno.71086","article-title":"Pyroptosis in inflammatory diseases and cancer","volume":"12","author":"Rao","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.109537_bb0360","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","article-title":"NLRP3 and pyroptosis blockers for treating inflammatory diseases","volume":"43","author":"Coll","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0365","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1007\/s12013-024-01443-1","article-title":"CMPK2 Promotes CD4(+) T Cell Activation and Apoptosis through Modulation of Mitochondrial Dysfunction in Systemic Lupus Erythematosus","volume":"82","author":"Tan","year":"2024","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.bioorg.2026.109537_bb0370","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.21037\/atm-21-6193","article-title":"ZBP1 is a significant pyroptosis regulator for systemic lupus erythematosus","volume":"9","author":"Huang","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.109537_bb0375","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1016\/j.ymthe.2025.06.034","article-title":"Targeting NLRP3\/caspase-1\/GSDMD to treat inner ear injury from labyrinthine hemorrhage","volume":"33","author":"Wu","year":"2025","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.bioorg.2026.109537_bb0380","article-title":"Melatonin Attenuates Methamphetamine Neurotoxicity through inhibition of NLRP3 and pyroptosis pathway","volume":"28","author":"Rashidi","year":"2024","journal-title":"Physiol. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175091","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","volume":"928","author":"Li","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0390","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116261","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus","volume":"172","author":"Wu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109537_bb0400","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20242403","article-title":"Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action","volume":"222","author":"Wilhelmsen","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2026.109537_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111844","article-title":"Anti-cancer effects of Tranilast: An update","volume":"141","author":"Osman","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109537_bb0410","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1186\/s12967-024-05951-9","article-title":"Novel approach to alleviate lupus nephritis: targeting the NLRP3 inflammasome in CD8(+)CD69(+)CD103(+) T(RM) cells","volume":"22","author":"Lai","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.109537_bb0415","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3389\/fimmu.2019.02578","article-title":"OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis","volume":"10","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0420","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13075-018-1664-2","article-title":"NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis","volume":"20","author":"Marchetti","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bioorg.2026.109537_bb0425","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.2174\/0929867329666220922104654","article-title":"The Selective NLRP3-Inflammasome Inhibitor CY-09 Ameliorates Kidney Injury in Diabetic Nephropathy by Inhibiting NLRP3- inflammasome Activation","volume":"30","author":"Yang","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109537_bb0430","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.pmch.2019.11.002","article-title":"P2X7 receptor antagonists for the treatment of systemic inflammatory disorders","volume":"59","author":"Gelin","year":"2020","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109537_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114205","article-title":"ATP ion channel P2X purinergic receptors in inflammation response","volume":"158","author":"Liu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109537_bb0440","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41401-021-00619-2","article-title":"Caspase-11 promotes NLRP3 inflammasome activation via the cleavage of pannexin1 in acute kidney disease","volume":"43","author":"Yin","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2026.109537_bb0445","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1681\/ASN.2014070721","article-title":"The dark side of extracellular ATP in kidney diseases","volume":"26","author":"Solini","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bioorg.2026.109537_bb0450","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.20172222","article-title":"Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity","volume":"215","author":"Boucher","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2026.109537_bb0455","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.freeradbiomed.2022.02.027","article-title":"Silica nanoparticles induce pyroptosis and cardiac hypertrophy via ROS\/NLRP3\/Caspase-1 pathway","volume":"182","author":"Wang","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bioorg.2026.109537_bb0460","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","article-title":"NLRP3 inflammasome activation and cell death","volume":"18","author":"Huang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0465","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3389\/fimmu.2019.02538","article-title":"Pharmacological Inhibitors of the NLRP3 Inflammasome","volume":"10","author":"Zahid","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115861","article-title":"Interleukin-1\u03b2 converting enzyme (ICE): A comprehensive review on discovery and development of caspase-1 inhibitors","volume":"261","author":"Modi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109537_bb0475","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bmc.2006.11.011","article-title":"Synthesis and evaluation of unsaturated caprolactams as interleukin-1beta converting enzyme (ICE) inhibitors","volume":"15","author":"Wang","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109537_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2024.104810","article-title":"The research progression of direct NLRP3 inhibitors to treat inflammatory disorders","volume":"397-398","author":"Chen","year":"2024","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118164","article-title":"Mechanisms and therapeutic potential of pharmacological agents targeting inflammasomes","volume":"189","author":"Li","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109537_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129675","article-title":"The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening","volume":"102","author":"Hartman","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109537_bb0495","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.phrs.2014.10.009","article-title":"Tranilast: a review of its therapeutic applications","volume":"91","author":"Darakhshan","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109537_bb0500","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11926-021-00984-1","article-title":"A Review of Complement Activation in SLE","volume":"23","author":"Weinstein","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bioorg.2026.109537_bb0505","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5460302","article-title":"Natural Compounds as Regulators of NLRP3 Inflammasome-Mediated IL-1\u03b2 Production","volume":"2016","author":"T\u0151zs\u00e9r","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bioorg.2026.109537_bb0510","doi-asserted-by":"crossref","DOI":"10.1007\/s12013-025-01723-4","article-title":"Targeting the NLRP3 by Natural Compounds: Therapeutic Strategies to Mitigate Doxorubicin-Induced Cardiotoxicity","author":"Shackebaei","year":"2025","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.bioorg.2026.109537_bb0515","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.14336\/AD.2021.0318","article-title":"Targeting NLRP3 Inflammasome in the Treatment Of Diabetes and Diabetic Complications: Role of Natural Compounds from Herbal Medicine","volume":"12","author":"Bai","year":"2021","journal-title":"Aging Dis."},{"key":"10.1016\/j.bioorg.2026.109537_bb0520","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2024.2319203","article-title":"Animal models of lupus nephritis: the past, present and a future outlook","volume":"57","author":"Katikaneni","year":"2024","journal-title":"Autoimmunity"},{"key":"10.1016\/j.bioorg.2026.109537_bb0525","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/10286020.2025.2482054","article-title":"Baicalin: an active natural product with potential medicinal values","volume":"27","author":"Wen","year":"2025","journal-title":"J. Asian Nat. Prod. Res."},{"key":"10.1016\/j.bioorg.2026.109537_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2025.102795","article-title":"Baicalin reduced vandetanib induced myocardial injury by regulating redox balance and NLRP3 inflammasome pathway","volume":"94","author":"Wang","year":"2025","journal-title":"Tissue Cell"},{"key":"10.1016\/j.bioorg.2026.109537_bb0535","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/cns.13086","article-title":"Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4\/NF-\u03baB signaling pathway","volume":"25","author":"Jin","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bioorg.2026.109537_bb0540","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.2147\/DDDT.S379629","article-title":"Baicalin Alleviates Contrast-Induced Acute Kidney Injury Through ROS\/NLRP3\/Caspase-1\/GSDMD Pathway-Mediated Proptosis in vitro","volume":"16","author":"Li","year":"2022","journal-title":"Drug Design, Dev. Ther."},{"key":"10.1016\/j.bioorg.2026.109537_bb0545","article-title":"Overview of Oxidative Stress in Systemic Lupus Erythematosus","volume":"14","author":"Lupu","year":"2025","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0550","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.apsb.2024.10.004","article-title":"Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications","volume":"15","author":"Dash","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.109537_bb0555","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/1535370216647181","article-title":"Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux","volume":"241","author":"Voloshyna","year":"2016","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.bioorg.2026.109537_bb0560","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.metabol.2014.02.003","article-title":"Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation","volume":"63","author":"Yang","year":"2014","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bioorg.2026.109537_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115049","article-title":"Resveratrol derivative SH-707 inhibits NLRP3 inflammasome activation via a sirtuin 1-dependent pathway","volume":"161","author":"Kim","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0570","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/09731296241229242","article-title":"Resveratrol Suppresses \"Metabolic Memory\" by Inhibiting Inflammation and Apoptosis Through the ROS\/TXNIP\/NLRP3 Signaling Pathway","volume":"20","author":"Jiang","year":"2024","journal-title":"Pharmacogn. Mag."},{"key":"10.1016\/j.bioorg.2026.109537_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156897","article-title":"Resveratrol reduces the activation of NLRP3 inflammasomes in rheumatoid arthritis through SIRT1 and ITGB \u03b1(5)\u03b2(1), especially in patients with high expression of ACPA","volume":"144","author":"Cai","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2026.109537_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2020.108489","article-title":"Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma","volume":"85","author":"Tian","year":"2020","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.bioorg.2026.109537_bb0585","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.64.15.28","article-title":"Resveratrol Alleviates Retinal Ischemia-Reperfusion Injury by Inhibiting the NLRP3\/Gasdermin D\/Caspase-1\/Interleukin-1\u03b2 Pyroptosis Pathway","volume":"64","author":"Xie","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911678","article-title":"Resveratrol Mitigates Oxygen and Glucose Deprivation-Induced Inflammation, NLRP3 Inflammasome, and Oxidative Stress in 3D Neuronal Culture","volume":"23","author":"Chiang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0600","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109537_bb0605","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s10753-021-01439-6","article-title":"The Signaling Pathways Regulating NLRP3 Inflammasome Activation","volume":"44","author":"Chen","year":"2021","journal-title":"Inflammation"},{"key":"10.1016\/j.bioorg.2026.109537_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111888","article-title":"Pharmacological properties and underlying mechanisms of curcumin and prospects in medicinal potential","volume":"141","author":"Fu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109537_bb0615","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.intimp.2019.01.046","article-title":"Curcumin attenuates murine lupus via inhibiting NLRP3 inflammasome","volume":"69","author":"Zhao","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0620","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1007\/s10787-025-01926-4","article-title":"Targeting NLRP3 inflammasome with curcumin: mechanisms and therapeutic promise in chronic inflammation","volume":"33","author":"Pandey","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bioorg.2026.109537_bb0625","doi-asserted-by":"crossref","DOI":"10.3390\/jfb14010044","article-title":"Icariin: A Promising Natural Product in Biomedicine and Tissue Engineering","volume":"14","author":"Seyedi","year":"2023","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.bioorg.2026.109537_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108861","article-title":"Impact of Icariin and its derivatives on inflammatory diseases and relevant signaling pathways","volume":"108","author":"Luo","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0635","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/2211-5463.12161","article-title":"Icariin ameliorates IgA nephropathy by inhibition of nuclear factor kappa b\/Nlrp3 pathway","volume":"7","author":"Zhang","year":"2017","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bioorg.2026.109537_bb0640","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.intimp.2015.11.035","article-title":"Icariin attenuates cerebral ischemia-reperfusion injury through inhibition of inflammatory response mediated by NF-\u03baB, PPAR\u03b1 and PPAR\u03b3 in rats","volume":"30","author":"Xiong","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0645","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lfs.2018.07.009","article-title":"Icariin alleviates murine lupus nephritis via inhibiting NF-\u03baB activation pathway and NLRP3 inflammasome","volume":"208","author":"Su","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2026.109537_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154005","article-title":"Icariin protects podocytes from NLRP3 activation by Sesn2-induced mitophagy through the Keap1-Nrf2\/HO-1 axis in diabetic nephropathy","volume":"99","author":"Ding","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2026.109537_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2023.136101","article-title":"Procyanidin B2: A promising multi-functional food-derived pigment for human diseases","volume":"420","author":"Chen","year":"2023","journal-title":"Food Chem."},{"key":"10.1016\/j.bioorg.2026.109537_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2025.115341","article-title":"Procyanidin B2 mitigates methotrexate-induced hepatic pyroptosis by suppressing TLR4\/NF-\u03baB and caspase-3\/GSDME pathways","volume":"199","author":"Alsaab","year":"2025","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bioorg.2026.109537_bb0665","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/1753425918780985","article-title":"Procyanidin B2 prevents lupus nephritis development in mice by inhibiting NLRP3 inflammasome activation","volume":"24","author":"He","year":"2018","journal-title":"Innate Immunity"},{"key":"10.1016\/j.bioorg.2026.109537_bb0670","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biopha.2017.10.064","article-title":"Chlorogenic acid (CGA): A pharmacological review and call for further research","volume":"97","author":"Naveed","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109537_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0316615","article-title":"Chlorogenic acid inhibits NLRP3 inflammasome activation through Nrf2 activation in diabetic nephropathy","volume":"20","author":"Bao","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.109537_bb0680","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1039\/C8FO01281D","article-title":"Chlorogenic acid methyl ester exerts strong anti-inflammatory effects via inhibiting the COX-2\/NLRP3\/NF-\u03baB pathway","volume":"9","author":"Zhang","year":"2018","journal-title":"Food Funct."},{"key":"10.1016\/j.bioorg.2026.109537_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107571","article-title":"Chlorogenic acid can improve spermatogenic dysfunction in rats with varicocele by regulating mitochondrial homeostasis and inhibiting the activation of NLRP3 inflammasomes by oxidative mitochondrial DNA and cGAS\/STING pathway","volume":"150","author":"Jia","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109537_bb0690","article-title":"Recent developments on ursolic acid and its potential biological applications","volume":"14","author":"Arulnangai","year":"2025","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.bioorg.2026.109537_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155556","article-title":"Ursolic acid alleviates lupus nephritis by suppressing SUMO1-mediated stabilization of NLRP3","volume":"130","author":"Chen","year":"2024","journal-title":"Phytomedicine"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:13:08Z","timestamp":1770973988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":139,"alternative-id":["S0045206826000738"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109537","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of the NLRP3 pathway as a strategy for SLE therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109537"}}